Additionally , subgroup analyses of patients with ( 1 ) multiple tumors or a single tumor 2 cm ; and ( 2 ) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage ( 56.8 % improvement in disease-free survival , P = 0.045 ) for patients with both risk factors for recurrence .